ASH 2020 Meeting Highlights in Multiple Myeloma

ASH 2020 Meeting Highlights in Multiple Myeloma
ASH 2020 Meeting Highlights in Multiple Myeloma
CME, CPE, CNE
Joshua Richter, MD; Adam D. Cohen, MD; Nina Shah, MD
Release Date: March 10, 2021
Expiration Date: March 10, 2022

In this activity, experts will discuss a selection of key abstracts from the 2020 ASH Annual Meeting and describe how this data can be applied to clinical practice. Topics will include an update analysis of the GRIFFIN trial, review of BiTE therapy including the first-in-human study of talquetamab, CAR T-cell therapy, updated real-world results from the community-based US MM-6 study looking at iCT from parenteral bortezomib to oral ixazomib PI therapy, and the long-term follow-up analysis of the IFM 2009 trial looking at early versus late ASCT in newly diagnosed myeloma.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Takeda Oncology.

Begin, Earn CreditView Only, No Credit